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ABSTRACT
One of the features of liver cirrhosis is an abnormal metabolism of
methionine—a characteristic that was described more than a half
a century ago. Thus, after an oral load of methionine, the rate of
clearance of this amino acid from the blood is markedly impaired
in cirrhotic patients compared with that in control subjects. Almost
15 y ago we observed that the failure to metabolize methionine in
cirrhosis was due to an abnormally low activity of the enzyme
methionine adenosyltransferase (EC 2.5.1.6). This enzyme con-
verts methionine, in the presence of ATP, to S-adenosyl-L-methionine
(SAMe), the main biological methyl donor. Since then, it has been
suspected that a deficiency in hepatic SAMe may contribute to the
pathogenesis of the liver in cirrhosis. The studies reviewed here
are consistent with this hypothesis. Am J Clin Nutr
2002;76(suppl):1177S–82S.
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BIOSYNTHESIS AND METABOLISM OF
S-ADENOSYL-L-METHIONINE
S-Adenosyl-L-methionine (SAMe) is synthesized from
L-methionine and ATP in a 2-step reaction where the complete
tripolyphosphate moiety is cleaved from ATP as SAMe is being
formed. This rather unusual reaction is catalyzed by the enzyme
methionine adenosyltransferase (MAT, also known as SAMe-
synthetase; EC 2.5.1.6) (1, 2). In the first step, SAMe is formed by
a direct attack of the sulfur atom of methionine on the C-5 atom
of ATP, with cleavage of the complete tripolyphosphate moiety
from ATP. In the second step, the tripolyphosphate thus generated
is hydrolyzed asymmetrically to orthophosphate and pyrophos-
phate. The 3 products of the reaction (orthophosphate, pyrophos-
phate, and SAMe) are then released simultaneously. MAT can also
hydrolyze exogenously added tripolyphosphate. The cloning and
sequencing of the structural genes or complementary DNA encod-
ing for a large variety of MATs in different organisms and tissues
(including Mycoplasma genitalium, Escherichia coli, Saccha-
romyces cerevisiae, Arabidopsis thaliana, and mice, rat, and
human kidney and liver tissue) have shown that MAT is an excep-
tionally well-conserved enzyme through evolution (3). Thus,
MAT from E. coli and humans share 59% sequence identity (4).
Analyses of genome sequences from archaea, eubacteria, fungi,
plants, and animals indicate that all organisms synthesize SAMe
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and that a surprisingly large fraction of all genes are SAMe-
dependent methyltransferases. The crucial importance of the liver
in the regulation of blood methionine concentrations was first
established by Kinsell et al in 1947 (5). These authors showed a
marked impairment of methionine metabolism in patients with
liver cirrhosis. Later work, mainly in the laboratories of Mudd and
Poole (6) and Finkelstein (7), showed that under normal condi-
tions, both in men and rats, ≤ 85% of all methylation reactions and
50% of methionine metabolism occur in the liver (6, 7). In addi-
tion, these authors estimated that the half-life of SAMe in the liver
is 5 min. In normal liver, most SAMe is used in methylation
reactions because the SAMe decarboxylation pathway accounts
for < 10% of the available SAMe (Figure 1). In humans, the
fraction of available homocysteine converted to cystathionine
during each cycle is 53% and this percentage drops to 20%
when the dietary content of methyl groups is restricted, as a way
to preserve methionine consumption. A central role of SAMe in
the regulation of hepatic methionine metabolism was first pro-
posed by Finkelstein et al (8–10) on the basis of their findings
that SAMe activates cystathionine -synthase (EC 4.2.1.22) and
betaine–homocysteine S-methyltransferase (EC 2.1.1.5) and on
the earlier observation by Kutzbach and Stokstad (11, 12) that
SAMe inhibits methylenetetrahydrofolate reductase (EC 1.7.99.5).
Thus, during each cycle, hepatic SAMe regulates the fraction of
homocysteine that is methylated to form methionine and the frac-
tion that is taken into the transsulfuration pathway. A high hepatic
SAMe content, usually the result of a high blood methionine con-
centration, activates the flow of homocysteine through the
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FIGURE 1. Hepatic methionine (Met) metabolism. Met is con-
verted to homocysteine (Hcy) via S-adenosyl-L-methionine (SAMe)
and S-adenosylhomocysteine (SAH). The conversion of Met into SAMe is
catalyzed by the enzyme methionine adenosyltransferase (MAT; EC 2.5.1.6).
After decarboxylation, SAMe can donate the remaining propylamino moi-
ety attached to its sulfonium ion to putrescine [to form spermidine and
methylthioadenosine (MTA)] and to spermidine (to form spermine and a
second molecule of MTA). SAMe donates its methyl group in a large
variety of reactions catalyzed by dozens of methyltransferases (MTs),
the most abundant in the liver being glycine methyltransferase (GNMT;
EC 2.1.1.20). The SAH thus generated is hydrolyzed to form Hcy and
adenosine through a reversible reaction catalyzed by the enzyme SAH
hydrolase (EC 3.3.1.1). Two enzymes catalyze the methylation of Hcy to
form methionine: methionine synthase (MS; EC 2.1.1.13) and betaine
methyltransferase (BHMT; EC 2.1.1.5). MTA can be recycled back to
methionine in a methionine biosynthetic pathway initiated by the enzyme
MTA-phosphorylase (MTAP; EC 2.4.2.28). Hcy, in the presence of serine,
forms cystathionine in a reaction catalyzed by the enzyme cystathionine
-synthetase (CBS; EC 4.2.1.22). Cystathionine is then hydrolyzed to form
cysteine, which is a precursor of the synthesis of glutathione (GSH). THF,
tetrahydrofolate; 5,10-MTHF, 5,10-methylenetetrahydrofolate; 5-MTHF,
5-methyltetrahydrofolate; X, methyl acceptor molecule; X-CH3, methy-
lated molecule.
transsulfuration pathway, whereas low concentrations of SAMe
enhance methionine conservation.
MAMMALIAN MATs
In mammals there are 2 genes encoding MATs: MAT1A and
MAT2A (7). Whereas MAT1A is only expressed in the adult liver,
MAT2A is expressed in all tissues, including fetal liver, hepato-
cellular carcinoma, and in small amounts in the adult liver (13).
MAT1A encodes a catalytic subunit 1 that organizes into dimers
(MAT III) and tetramers (MAT I), whereas MAT2A encodes a cat-
alytic subunit 2 that associates to form MAT II (13). The 1 and
2 subunits share an amino acid sequence identity of 84% (13).
The main difference between MAT1A and MAT2A is that MAT I
and MAT III, the enzymes encoded by MAT1A, can maintain
higher intracellular SAMe concentrations than can MAT II, the
enzyme encoded by MAT2A (13). This is because of differences in
the kinetic and regulatory properties of the enzymes. Although the
combination of MAT I and MAT III provides the cell with a set of
enzymes capable of efficiently metabolizing methionine over a
large range of physiologic concentrations of this amino acid and
without being inhibited by the intracellular accumulation of
SAMe, the product of the reaction. MAT II has a high affinity but
a low capacity to metabolize methionine and is strongly inhibited
by SAMe at concentrations in the micromoles per liter range (13).
REGULATION OF MAT I AND MAT III ACTIVITIES BY
REACTIVE OXYGEN SUBSTANCES AND NITRIC OXIDE
Nitric oxide (NO) and reactive oxygen substances (ROS) have
been shown to switch both MAT I and MAT III to an inactive con-
formation through S-nitrosylation (formation of an SNO group)
and oxidation (formation of an SOH group) of a single cysteine
residue in position 121 (C-121), respectively. The 1 subunit from
which MAT I and MAT III are made contains 10 cysteine residues.
It has been shown that only replacement of cysteine 121 by serine
(Cys121→Ser) yields an active enzyme that is resistant to NO and
ROS inactivation (14, 15). Replacement, one by one, of all other
cysteine residues by serine yields active enzymes that are inacti-
vated by both NO and ROS, just as the wild-type enzyme (14, 15).
Cysteine 121 is located over the active site of the enzyme, in a
flexible loop, suggesting that the covalent modification of this
thiol group switches MAT I and MAT III into an inactive confor-
mation (16). Protein S-nitrosylation involves an acid-base–cat-
alyzed SNO-SH exchange reaction where the target cysteine is
surrounded by basic and acidic amino acids that reduce the pKa of
its thiol group and make it more nucleophilic (17). Accordingly,
MAT S-nitrosylation has been shown to be regulated by the basic
(Arg357 and Arg363) and acidic (Asp355) amino acids surround-
ing the target thiol, and replacement of any of these 3 residues by
serine markedly reduces the capacity of NO to S-nitrosylate and
inactivate liver MAT (16). In MAT II, Arg357, Arg363, and
Asp355 are conserved, but the equivalent position to Cys121 in
MAT I and MAT III is occupied by a residue of glycine (Gly120).
Accordingly, MAT II is not inactivated by NO, but the replace-
ment of Gly120 by cysteine (Gly120) yields an active enzyme
that, in the presence of NO donors, is S-nitrosylated and inacti-
vated (18). An alignment of a large variety of MATs, cloned from
bacteria, yeast, plants, Drosophila, and mice, rat, and human kid-
ney and liver tissue have shown that the presence of a cysteine
residue in position 121 is a characteristic of the liver enzymes and
that all other MATs have a different amino acid in this position,
most frequently a residue of glycine.
Inactivation of MAT I and MAT III by NO or ROS is reversed
by physiologic (millimolar) concentrations of glutathione (14, 19,
20). In isolated rat hepatocytes, incubation with NO donors or
inhibition of glutathione synthesis induces the S-nitrosylation and
inactivation of MAT and a reduction in SAMe content (21).
Removal of the NO donor from the incubation media or restora-
tion of the cellular glutathione concentrations leads to the deni-
trosylation and reactivation of liver MAT and to the rapid recov-
ery of the SAMe content (21). The intraperitoneal injection of
bacterial lipopolysaccharide to rats also results in the S-nitrosylation
and inactivation of hepatic MAT (19). Similarly, inhibition in rats
of glutathione H synthesis by intraperitoneal injection of buthio-
nine sulfoximine leads to the S-nitrosylation and inactivation of
hepatic MAT (21, 22).
In summary, liver MAT I and MAT III activities seem to be pre-
cisely regulated by NO and ROS (which maintain the enzyme in
an inactive conformation) and by glutathione (which reactivates
the enzyme). The inactivation of MAT I and II by NO or ROS may
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FIGURE 2. Regulation of the expression of MAT1A by methylation of
the gene promoter and its association with nonacetylated histones. In the
normal adult liver, MAT1A is transcriptionally competent and its promoter
is demethylated and associated with acetylated histones. On the contrary,
in extrahepatic tissues, fetal liver, hepatocellular carcinoma, and advanced
states of liver cirrhosis (Child class C), MAT1A is transcriptionally incom-
petent and its promoter is methylated and associated with nonacetylated
histones. In less advanced states of cirrhosis (Child classes A and B),
MAT1A expression is partially silenced but can be induced (ie, by treat-
ment with S-adenosyl-L-methionine).
be the mechanism by which a variety of conditions that induce
oxidative stress (septic shock, ethanol, carbon tetrachloride, and
hepatitis B– and hepatitis C–induced liver cirrhosis), or increase
NO synthesis (hypoxia, liver regeneration, and cytokines), inacti-
vate hepatic MAT I and III (14, 23–27). Moreover, these results
suggest that liver MAT I and III inactivation may be a key signal
to respond to injury.
REGULATION OF MAT1A AND MAT2A EXPRESSION
Functional analysis by transient transfection has shown that the
rat MAT1A promoter is active not only in hepatocytes and liver-
type cells, such as the human hepatoma cell line HepG2, but also
in a nonhepatic cell such as Chinese hamster ovary cells (28).
These findings suggest that the liver-restricted expression of the
endogenous gene may not be mediated by the action of tissue-
specific factors. It was then found that MAT1A promoter is hyper-
methylated at a CpG site in extrahepatic tissues and fetal liver but
unmethylated in adult liver, where the gene is actively transcribed
(29, 30). It has been shown that elevated concentrations of histone
acetylation are critical to maintain a decondensed and active state
of the chromatin, and the underlying pattern of CpG methylation
modulates histone acetylation (31, 32). Accordingly, the degree of
acetylation of histones associated with MAT1A promoter in the
liver is 15-fold higher than that observed in the kidney (29, 30).
In rat- and human-derived hepatoma cell lines and in human hepa-
tocellular carcinoma, MAT1A is expressed at reduced or unde-
tectable concentrations, whereas MAT2A expression is markedly
induced (33, 34). Regarding the mechanisms behind the silencing
of MAT1A expression during liver neoplastic transformation, it has
been found that MAT1A is hypermethylated in HepG2 cells and
that the treatment of these cells with the demethylating agent
5-aza-2-deoxycytidine or the histone deacetylase inhibitor trico-
statin A results in the induction of MAT1A expression (30). Taken
together, these observations indicate that mechanisms involving
DNA methylation and histone deacetylation may be the main fac-
tors responsible for the liver-restricted expression of MAT1A and
for its silencing in neoplastic transformation (Figure 2).
In human liver cirrhosis, independently of the etiology (alco-
hol, hepatitis B, hepatitis C, etc), MAT1A is expressed at reduced
and in some cases undetectable concentrations, whereas the
expression of MAT2A remains low (34). It has been shown that
MAT1A promoter is hypermethylated in the liver of cirrhotic
patients (34), suggesting that this and the increased production of
ROS and NO may be responsible for the impaired hepatic MAT
activity (33, 34), increased serum concentrations of methionine
(24, 35), and abnormal clearance of this amino acid (5, 24, 36) in
human liver cirrhosis (Figure 2). Understanding why MAT1A
becomes hypermethylated in liver cirrhosis may have applications
in the treatment of this disease.
With respect to MAT2A, when the methylation pattern of
MAT2A promoter was analyzed, no differences were observed
between the liver and other tissues where the gene is actively tran-
scribed, such as the kidney and spleen (37). Moreover, this analy-
sis showed the same degree of methylation in all 3 tissues. How-
ever, differences in the degree of methylation have been observed
between normal liver and in human liver cancer; the human
MAT2A promoter is hypomethylated in hepatocellular carcinoma
but hypermethylated in normal liver (38). The reason for these dif-
ferences is not clear and the exact role of promoter methylation in
MAT2A expression remains to be established. Histones associated
with MAT2A promoter are hyperacetylated in kidney and
hypoacetylated in liver (31), suggesting that the low activity of
MAT2A in liver results from the inaccessibility of transcription
factors to binding sites within the condensed chromatin.
Liver regeneration is a fundamental feature of the response of
this organ to injury. Liver mass loss, caused by hepatotoxins or
partial hepatectomy, initiates a cellular response—involving a vast
number of growth factors, cytokines, and transcription factors—
that has positive and negative effects on liver until the restoration
of normal hepatic architecture and function (39). In regenerating
liver after partial hepatectomy, a switch in MAT gene expression
has been observed: MAT2A is induced and MAT1A messenger
RNA (mRNA) concentrations decrease (40–42). The induction of
MAT2A expression is accompanied by a marked increase in the
acetylation of the histones associated with this gene (42). In cul-
ture hepatocytes, MAT2A expression is induced and MAT1A
mRNA concentrations decrease (43), a situation reminiscent of
that found in fetal and regenerating liver and in hepatocellular car-
cinoma. Addition of hepatocyte growth factor (HGF, a potent
mitogen for hepatocytes that plays a key role in liver regeneration)
to culture hepatocytes markedly stimulates the acetylation of his-
tones associated with MAT2A and the expression of the gene (43).
The effect of HGF on MAT2A expression is prevented by SAMe
(43). On the other hand, the reduction in MAT1A expression in
hepatocytes in culture is suppressed by SAMe through a mecha-
nism that remains unclear but that may involve protein methyla-
tion (43). In HepG2 and HuH-7 cells differing only in the type of
MAT gene that is expressed, MAT2A expression associates with
 at UNIVERSIDAD DE NAVARRA BIBLIO
TECA HUM









1180S MARTÍNEZ-CHANTAR ET AL
FIGURE 3. In response to liver injury, both the expression and
activity of methionine adenosyltransferase (MAT; EC 2.5.1.6) I and
III are switched off and MAT II expression is switched on. As a con-
sequence of this switch in MAT expression, the hepatic content of
S-adenosyl-L-methionine (SAMe) changes to a new lower steady state
concentration, which facilitates the progression of the cell division
cycle and hepatocyte growth.
more rapid cell growth, whereas the opposite situation is observed
for MAT1A (44). Cells expressing MAT2A had lower SAMe con-
centrations than did cells expressing MAT1A, and treatment of
HuH-7 cells with SAMe also led to reduced cell growth (44).
These data suggest that SAMe has a growth-modulatory effect. In
fact, addition of SAMe to culture hepatocytes has been found to
markedly inhibit the mitogenic activity of HGF (43). Interestingly,
SAMe therapy has been shown to be effective in preventing the
growth of rat hepatocellular carcinoma (45, 46). These findings
provide a new and unexpected view of SAMe as a modulator of
hepatocyte proliferation.
In summary, the available data indicate that the SAMe content
in hepatocytes regulates the type of MAT gene that is expressed
and that the type of MAT gene expressed strongly influences the
rate of cell growth and DNA synthesis. As mentioned above, the
main difference between MAT1A and MAT2A is that MAT I and
MAT III, the enzymes encoded by MAT1A, can maintain higher
intracellular SAMe concentrations than can MAT II, the enzyme
encoded by MAT2A. Under normal conditions, MAT I and MAT
III are the main enzymes present in the liver and the hepatic SAMe
content is maintained high. Consequently, MAT1A is highly
expressed and MAT2A mRNA concentrations remain very low.
Liver mass loss, caused by hepatotoxins or partial hepatectomy,
initiates a cellular response involving a vast number of growth fac-
tors and cytokines (eg, HGF, tumor necrosis factor , and inter-
leukin 6) and the generation of NO and ROS (39, 47, 48). This
leads to the inactivation of MAT I and MAT III and a concomitant
reduction in the SAMe content, which in turn produces a reduction
in MAT1A expression and a further decrease in the activity of
MAT I and MAT III and in SAMe synthesis. The reduction in
SAMe content releases the inhibition that this molecule exerts on
the mitogenic activity of HGF as well as on the expression of
MAT2A. As a whole, in response to liver injury, the expression and
activity of MAT I and MAT III is switched off and MAT II
expression is switched on and the hepatic content of SAMe
changes to a new lower steady state concentration; this facilitates
the progression of the cell division cycle and hepatocyte growth
(Figure 3). During restoration of the original liver mass, the
inhibitory effect that NO and ROS exert on the activity of MAT I
and MAT III is released, MAT1A expression is induced, the SAMe
content increases, and MAT2A expression is again switched off,
which may help the liver to recover its normal nonproliferative
metabolic phenotype.
IMPORTANCE OF A DEFICIENCY IN SAMe SYNTHESIS
IN THE PATHOGENESIS OF LIVER INJURY
To examine the hepatic consequences of a chronic reduction in
SAMe, we recently generated a knockout mouse deficient in
hepatic MAT synthesis (49). As expected, MAT1A null (MATO)
mice have a marked elevation in blood methionine and a low
hepatic SAMe content with respect to wild-type animals (49).
Three-month-old mice, although histologically normal, have
hepatic hyperplasia and are more prone to develop liver steatosis
after being fed a diet deficient in choline than are wild-type mice
(49). Moreover, carbon tetrachloride–induced injury of the liver,
determined histologically and on the basis of serum concentra-
tions of alanine transaminase (EC 2.6.1.2) and aspartate transam-
inase (EC 2.6.1.1), was much more intense in MATO mice than
in wild-type mice. At 8 mo of age, MATO mice develop steato-
hepatitis (49). Three-month-old MATO mice, although histologi-
cally normal, display a phenotype that resembles that observed in
liver injury or during stress with a vast array of growth, dediffer-
entiation, and acute phase response genes (eg, proliferating cell
nuclear antigen, -fetoprotein, MAT2A, and orosomucoid) up-
regulated (49). This indicates that, at the molecular level, the
hepatic lesion has started long before it is histologically evident.
Because hepatic hyperplasia may precede the appearance of liver
cancer (50), it is important to know whether the risk of hepato-
cellular carcinoma is increased in MATO mice. These results
clearly indicate that a chronic deficiency in SAMe synthesis, such
as that observed in patients with liver cirrhosis, contributes to the
pathogenesis of liver injury.
USE OF SAMe AS A THERAPEUTIC AGENT FOR LIVER
DISEASE
In cirrhotic patients, the progressive silencing of MAT I and
MAT III (expression and activity) caused by this condition may
expose the liver to an additional oxidative stress that will con-
tribute to the progression and complications of the disease. Pre-
venting SAMe deficiency could be a major therapeutic target for
the treatment of human liver diseases. As reviewed elsewhere (51),
a variety of clinical studies indicate that SAMe treatment, given
either orally or parenterally, is beneficial in intrahepatic cholesta-
sis. Thus, in a double-blind, placebo-controlled, multicenter clin-
ical trial performed in 220 patients with chronic liver disease
(chronic active hepatitis and cirrhosis), SAMe treatment signifi-
cantly improved serum markers (bilirubin and alkaline phos-
phatase) and subjective symptoms (eg, pruritus and fatigue) of
cholestasis (52). Similar findings were obtained in a variety of
blind and open studies, and a meta-analysis of the results of these
studies confirmed the efficacy of the drug (53). In addition, SAMe
treatment was shown to be beneficial in severe cholestasis of preg-
nancy (54). These results clearly show that short-term adminis-
tration of SAMe improves the clinical and biochemical features
of cholestasis. Moreover, in patients with alcoholic liver disease,
oral administration of 1.2 g SAMe/d for 6 mo resulted in a signi-
ficant increase in hepatic glutathione (55). In animal models of
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alcoholic liver disease and carbon tetrachloride hepatotoxicity,
exogenous administration of SAMe prevented the depletion of
SAMe and glutathione concentrations and significantly amelio-
rated liver injury, including fibrosis (25, 56, 57).
On the basis of these experimental and clinical results, a study
was designed to investigate the effects of SAMe treatment (1.2 g/d,
orally) in 123 patients (106 men and 17 women) in a double-blind,
randomized, placebo-controlled, multicenter clinical trial over a
24-mo period (58). All patients had alcoholic liver cirrhosis, and
histologic confirmation of the diagnosis was available in 84% of
the cases. Seventy-five patients were in Child class A, 40 in class B,
and 8 in class C. The efficacy of the treatment was analyzed in
terms of mortality from any cause or liver transplantation during
a period of ≤ 2 y. The overall mortality from any cause or liver
transplantation at the end of the trial decreased from 30% in the
placebo group to 16% in the SAMe group, although the difference
was not significant (P = 0.077). When patients with more
advanced cirrhosis (Child class C; Figure 2) were excluded from
the analysis, the overall mortality from any cause or liver trans-
plantation was significantly greater in the placebo group than in
the SAMe group (29% compared with 12%, P = 0.025), and dif-
ferences between the 2 groups in the 2-y survival curves (defined
as the time to death or liver transplantation) were also significant
(P = 0.046). In summary, these results indicate that long-term
treatment with SAMe may improve survival or delay liver trans-
plantation in patients with alcoholic liver cirrhosis, especially in
those with less advanced liver disease. Furthermore, the results of
this study indicate that treatment with SAMe is safe and free of
secondary effects.
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